Larimar Therapeutics, Inc. (LRMR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 Q4 '13: 0 Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '14 Q1 '15 Q4 '15 Q3 '16 Q4 '17 Q3 '18 Q2 '19 Q1 '20

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q4 '13: -13.8M Q1 '14: -14.8M Q2 '14: -17.8M Q2 '15: -55.9M Q3 '15: -61.2M Q4 '15: -73.8M Q1 '16: -78.4M Q2 '16: -75.9M Q3 '16: -71M Q4 '16: -58.2M Q1 '17: -53.6M Q4 '17: -53M Q1 '18: -55.4M Q2 '18: -57.5M Q3 '18: -59.8M Q4 '18: -61.1M Q1 '19: -58.7M Q2 '19: -46.8M Q3 '19: -40.3M Q4 '19: -31.8M Q1 '20: -25.2M Q2 '20: -32.9M Q3 '20: -34.6M Q4 '20: -42.8M Q1 '21: -48.2M Q2 '21: -49.4M Q3 '21: -55.8M Q4 '21: -50.5M Q1 '22: -47.2M Q2 '22: -43.4M Q3 '22: -35.2M Q4 '22: -36.5M Q1 '23: -35.3M Q2 '23: -36.2M Q3 '23: -38M Q4 '23: -41.8M Q1 '24: -50.9M Q2 '24: -65.8M Q3 '24: -73.8M Q4 '24: -90.9M Q1 '25: -105.3M Q2 '25: -108.5M Q3 '25: -139.8M Q4 '25: -172.5M Q1 '26: -172.4M Q2 '26: -179M Q2 '15 Q4 '16 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '13: -14.1M Q1 '14: -14.9M Q2 '14: -18.2M Q2 '15: -56.8M Q3 '15: -62M Q4 '15: -74.3M Q1 '16: -78.5M Q2 '16: -75.8M Q3 '16: -70.6M Q4 '16: -57.9M Q1 '17: -53.2M Q4 '17: -52M Q1 '18: -55M Q2 '18: -57.4M Q3 '18: -59.9M Q4 '18: -61.4M Q1 '19: -50.1M Q2 '19: -38.1M Q3 '19: -31.6M Q4 '19: -24.3M Q1 '20: -26.3M Q2 '20: -33.9M Q3 '20: -35.5M Q4 '20: -42.5M Q1 '21: -47.9M Q2 '21: -49.2M Q3 '21: -55.7M Q4 '21: -50.6M Q1 '22: -47.5M Q2 '22: -43.5M Q3 '22: -35.1M Q4 '22: -35.4M Q1 '23: -32.9M Q2 '23: -32.6M Q3 '23: -33.4M Q4 '23: -36.9M Q1 '24: -45.1M Q2 '24: -58.3M Q3 '24: -64.8M Q4 '24: -80.6M Q1 '25: -95.2M Q2 '25: -99.8M Q3 '25: -132M Q4 '25: -165.7M Q1 '26: -166M Q2 '26: -172.6M Q2 '15 Q4 '16 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q2 '14: -17.8M Q3 '14: -20.7M Q4 '14: -28.2M Q1 '15: -35.3M Q2 '15: -43.5M Q3 '15: -53.3M Q4 '15: -59.6M Q1 '16: -66.2M Q2 '16: -66.4M Q3 '16: -61.3M Q4 '16: -52M Q1 '17: -45.9M Q4 '17: -43.8M Q1 '18: -45.4M Q2 '18: -48.5M Q3 '18: -49.5M Q4 '18: -51.5M Q1 '19: -50.7M Q2 '19: -33.9M Q3 '19: -26.6M Q4 '19: -22.7M Q1 '20: -19.1M Q2 '20: -34.9M Q3 '20: -40.3M Q4 '20: -42.2M Q1 '21: -44.5M Q2 '21: -43.1M Q3 '21: -44M Q4 '21: -42.1M Q1 '22: -38.4M Q2 '22: -35.1M Q3 '22: -28.8M Q4 '22: -27.6M Q1 '23: -27.6M Q2 '23: -27.5M Q3 '23: -30.8M Q4 '23: -33.5M Q1 '24: -36.3M Q2 '24: -42.9M Q3 '24: -58.3M Q4 '24: -70.8M Q1 '25: -86.9M Q2 '25: -92.3M Q2 '14 Q4 '15 Q4 '17 Q2 '19 Q4 '20 Q2 '22 Q4 '23 Q2 '25

Free Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q2 '14: -17.8M Q3 '14: -20.7M Q4 '14: -28.3M Q1 '15: -35.4M Q2 '15: -43.7M Q3 '15: -53.6M Q4 '15: -60.1M Q1 '16: -67.2M Q2 '16: -67.5M Q3 '16: -62.3M Q4 '16: -52.6M Q1 '17: -46.2M Q4 '17: -43.8M Q1 '18: -45.4M Q2 '18: -48.6M Q3 '18: -49.6M Q4 '18: -51.6M Q1 '19: -50.8M Q2 '19: -34M Q3 '19: -26.7M Q4 '19: -22.8M Q1 '20: -19.3M Q2 '20: -35M Q3 '20: -40.4M Q4 '20: -42.3M Q2 '25: -92.6M Q3 '14 Q3 '15 Q3 '16 Q1 '18 Q1 '19 Q1 '20 Q2 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '20: 9.4M Q3 '20: 16M Q1 '21: 16M Q2 '21: 16M Q3 '21: 18.3M Q1 '22: 18.3M Q2 '22: 18.3M Q3 '22: 22.2M Q1 '23: 43.9M Q2 '23: 43.9M Q3 '23: 43.9M Q1 '24: 53.6M Q2 '24: 63.8M Q3 '24: 63.8M Q1 '25: 64M Q2 '25: 64M Q3 '25: 78.3M Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '13: -19.54 Q1 '14: -20.78 Q2 '14: -19.37 Q2 '15: -2.32 Q3 '15: -2.40 Q4 '15: -2.77 Q1 '16: -2.89 Q2 '16: -2.78 Q3 '16: -2.59 Q4 '16: -2.12 Q1 '17: -1.95 Q4 '17: -1.91 Q1 '18: -2.01 Q2 '18: -2.09 Q3 '18: -2.04 Q4 '18: -1.95 Q1 '19: -1.72 Q2 '19: -1.76 Q3 '19: -2.77 Q4 '19: -2.57 Q1 '20: -3.32 Q2 '20: -3.92 Q3 '20: -3.14 Q4 '20: -3.83 Q1 '21: -3.49 Q2 '21: -3.07 Q3 '21: -3.35 Q4 '21: -2.94 Q1 '22: -2.67 Q2 '22: -2.35 Q3 '22: -1.80 Q4 '22: -1.38 Q1 '23: -1.04 Q2 '23: -0.76 Q3 '23: -0.60 Q4 '23: -0.84 Q1 '24: -0.96 Q2 '24: -1.11 Q3 '24: -1.14 Q4 '24: -1.31 Q1 '25: -1.50 Q2 '25: -1.57 Q3 '25: -1.94 Q4 '13 Q1 '16 Q1 '18 Q3 '19 Q1 '21 Q3 '22 Q1 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.